BNCT Recurrent Meningioma Indication Approved Overseas: A Leap from “Head and Neck” to “Intracranial”

On October 28, the BNCT treatment system NeuCure and the BNCT dose calculation software NeuCure Dose Engine were officially approved overseas for a new indication: recurrent meningioma. This expands BNCT’s indication range from head and neck tumors to intracranial tumors, bringing a new treatment option to patients with recurrent meningioma. On October 30, Sumitomo Heavy Industries, Ltd. issued an announcement.

1. Understanding Meningioma: The Most Common Primary Intracranial Tumor

Meningioma arises from the meningeal cells covering the brain and spinal cord and is one of the most common primary intracranial tumors. Most meningiomas are benign and slow-growing; however, because intracranial space is limited, an enlarging tumor can compress brain tissue, nerves, and blood vessels, causing symptoms such as headache, seizures, visual decline, and limb weakness.

The prevalence of meningioma increases with age. Rough estimates suggest there are approximately 1 million prevalent meningioma patients in China. For most newly diagnosed patients, surgical resection is the first-line treatment, sometimes followed by radiotherapy, and the overall prognosis is favorable.

2. Recurrent Meningioma: A Triple Dilemma

Some meningiomas—particularly atypical or anaplastic ones—have a high tendency to recur, and the tumor may regrow even after standard surgery and radiotherapy. For these patients, as conventional treatment options become progressively limited, every question of “what do we do next” carries a heavy burden of treatment anxiety. They are not simply facing “one more round of treatment” but a triple dilemma:

  • Limited room for repeat surgery — After multiple surgeries, local anatomy is altered and scar tissue forms, significantly increasing surgical risk and difficulty;
  • Cumulative radiotherapy dose has reached its limit — Normal brain tissue has limited radiation tolerance, and further external beam irradiation may cause radiation-induced brain injury;
  • Few systemic treatment options — Pharmacological therapies generally have limited efficacy against meningioma and cannot serve as a reliable long-term disease control strategy.

3. BNCT: Cell-Scale “Targeted Tumor Killing”

BNCT (Boron Neutron Capture Therapy) is a binary targeted radiotherapy technology. Its mechanism involves two steps: first, a boron-containing drug (such as Steboronine®) is infused and selectively accumulates in tumor cells; then, a neutron beam is directed at the tumor site. Neutrons react with boron-10, releasing alpha particles and lithium-7 particles with a range of only about one cell diameter—the killing effect is strictly confined to the scale of boron-containing tumor cells, with relatively limited damage to surrounding normal tissue.

Through “targeted boron drug + neutron irradiation,” BNCT achieves cell-scale targeted tumor killing, with a mechanism distinct from conventional external beam radiotherapy, offering a re-treatment option for patients with recurrent meningioma.

4. Clinical Practice in China: Pengbo (Hainan) Boron Neutron Hospital

Pengbo (Hainan) Boron Neutron Hospital is the first medical institution in China to provide BNCT treatment to patients, equipped with the same approved BNCT treatment system NeuCure and Steboronine® boron drug. The team led by President Wang Enmin has years of experience in tumor radiosurgery.

Since the hospital successfully completed its first patient treatment in March 2026, it had carried out nearly 60 BNCT clinical treatments as of October 2026. Once the recurrent meningioma indication is officially approved, the hospital’s treatment indication range will be further expanded, enabling it to provide related treatment services to such patients in China.

5. Patient Education Note

BNCT is not suitable for all meningioma patients. Its current positioning primarily targets patients with recurrent meningioma whose disease continues to progress after multiple surgeries and radiotherapies. For newly diagnosed patients, surgery and standard radiotherapy remain the main pathways. BNCT treatment requires rigorous multidisciplinary evaluation—including tumor location, size, prior treatment history, and overall health status—with a professional team determining suitability. Patients and families with relevant needs are advised to consult and undergo assessment at medical institutions qualified to provide BNCT treatment.

Conclusion

The overseas approval of the BNCT recurrent meningioma indication marks an important leap for this technology from “head and neck tumors” to “intracranial tumors.” For patients with recurrent meningioma who have long shuttled between surgery and radiotherapy, this is not merely the arrival of a new technology, but a message of hope that “there is still an option.”

Leave a reply